Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.

AIDS (London, England) - 30 Nov 2007

Waters Laura J, Mandalia Sundhiya, Gazzard Brian, Nelson Mark

Abstract excerpt

Suspected hypersensitivity is the main reason for the early discontinuation of abacavir. After the observation that the risk of hypersensitivity correlated with ethnicity, the presence of the HLA allele B5701 was found to be the strongest retrospective predictor of hypersensitivity. Two prospective cohorts have since demonstrated a significant reduction in abacavir hypersensitivity rates with the use of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Drug Hypersensitivity

Share to Histocompatibility Testing

Share to HIV Reverse Transcriptase

Share to HLA-B Antigens

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 18025891
DOI: 10.1097/QAD.0b013e328273bc07

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.PMID 18025891Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.Semantic proximity Read ↗

Current trends in screening across ethnicities for hypersensitivity to abacavir.Semantic proximity Read ↗

Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.Semantic proximity Read ↗

HLA-B*5701 testing to predict abacavir hypersensitivitySemantic proximity Read ↗

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Semantic proximity Read ↗

[HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].Semantic proximity Read ↗

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

[HLA-B*5701 and abacavir hypersensitivity reaction].Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.